US brand comparison

Wegovy vs Wegovy HD

In STEP UP, a head-to-head trial of the injections, mean weight change was −15.6% on semaglutide (Wegovy) and −18.7% on semaglutide (Wegovy HD) over 72 weeks. These brands contain semaglutide. Compare their approved uses, formulations, and self-pay prices. Products are not interchangeable.

Wegovy vs Wegovy HD: active ingredients, formulations, and manufacturers
Compare	Wegovy	Wegovy HD
Active ingredient	SemaglutideGLP-1	SemaglutideGLP-1
How it is taken	Injection Once weekly Tablet Once daily, on an empty stomach	7.2 mg injection Once weekly
Manufacturer	Novo Nordisk	Novo Nordisk

Direct evidence

What was actually compared

STEP UP

Peer-reviewed paper

Wegovy injection vs Wegovy HD

Adults with a BMI of at least 30, without diabetes.

1,407 participants · 72 weeks · Randomized, double-blind, with placebo and active control

Mean weight change (% of body weight)

Treatment-policy analysis, accounting for treatment discontinuation.

STEP UP: Mean weight change at 72 weeks. Treatment-policy analysis, accounting for treatment discontinuation.
Treatment & dose	Change
Semaglutide (Wegovy)2.4 mg weekly injection	−15.6%
Semaglutide (Wegovy HD)7.2 mg weekly injection	−18.7%
PlaceboWeekly injection	−3.9%

The 7.2 mg dose produced greater mean weight reduction than 2.4 mg or placebo. Gastrointestinal events and altered skin sensations were more frequent at 7.2 mg.

All groups also received a lifestyle intervention. This trial did not study tablets. The 2.4 mg result is from STEP UP, not STEP 1. Study averages do not predict an individual's result.

Read the paper PubMed abstractReviewed Sep 28, 2026

Weight-loss results by formulation

Each result belongs to its named trial and dose. Separate trials have different participants and methods; these figures are not a direct comparison.

Wegovy vs Wegovy HD: sourced weight-loss results by formulation
Compare	Wegovy	Wegovy HD
Injection evidence	−14.9% (-14.9% at 68 wks · STEP 1 · 2.4 mg weekly (Wegovy)) STEP 1 · -14.9% at 68 wks 2.4 mg weekly (Wegovy) Accounts for treatment discontinuation	−18.7% (-18.7% at 72 wks · STEP UP · 7.2 mg weekly (Wegovy HD)) STEP UP · -18.7% at 72 wks 7.2 mg weekly (Wegovy HD) Accounts for treatment discontinuation
Tablet evidence	−13.6% (-13.6% at 64 wks · OASIS 4 · 25 mg daily (Wegovy tablet)) OASIS 4 · -13.6% at 64 wks 25 mg daily (Wegovy tablet) Accounts for treatment discontinuation	No reviewed weight-loss result for this brand and formulation.

Product-specific costs

Entry price and maintenance price

Self-pay quotes, not insurance estimates. Each figure identifies the product, provider, and dose where published.

Wegovy vs Wegovy HD: published self-pay prices by formulation
Compare	Wegovy	Wegovy HD
Injection prices	Advertised entry price $199/fill initially 28-day supply ≈ $213.21 per 30 days at this quoted rate Offer through Dec 31, 2026 Checked Sep 30, 2026 Wegovy pen (standard doses 0.25-2.4 mg) NovoCare (Novo Nordisk) · Manufacturer direct first two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026 Price conditions first two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026 After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply. 28-day supply Published maintenance dose $349/28 days 28-day supply ≈ $373.93 per 30 days at this quoted rate Checked Sep 30, 2026 At 2.4 mg Wegovy pen (standard doses 0.25-2.4 mg) NovoCare (Novo Nordisk) · Manufacturer direct Published price at 2.4 mg Price conditions Published price at 2.4 mg After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply. One price for every standard dose (0.25-2.4 mg). 28-day supply	Advertised entry price $399/28 days 28-day supply ≈ $427.50 per 30 days at this quoted rate Checked Sep 30, 2026 Wegovy HD pen (7.2 mg) NovoCare (Novo Nordisk) · Manufacturer direct self-pay cash, 7.2 mg dose Price conditions self-pay cash, 7.2 mg dose One box contains four weekly pens. This is the HD maintenance dose, not a treatment starting dose. The $199 introduction applies only to 0.25 and 0.5 mg standard Wegovy. Prescription, eligibility and restrictions apply. 28-day supply Published maintenance dose $399/28 days 28-day supply ≈ $427.50 per 30 days at this quoted rate Checked Sep 30, 2026 At 7.2 mg Wegovy HD pen (7.2 mg) NovoCare (Novo Nordisk) · Manufacturer direct Published price at 7.2 mg Price conditions Published price at 7.2 mg One box contains four weekly pens. This is the HD maintenance dose, not a treatment starting dose. The $199 introduction applies only to 0.25 and 0.5 mg standard Wegovy. Prescription, eligibility and restrictions apply. 28-day supply
Tablet prices	Advertised entry price from $149/mo 30-day supply $149 per 30 days at this quoted rate Checked Sep 30, 2026 Wegovy pill (oral semaglutide) NovoCare (Novo Nordisk) · Manufacturer direct self-pay cash, lowest dose (1.5 mg) Price conditions self-pay cash, lowest dose (1.5 mg) $149/mo for 1.5 mg; $199 for 4 mg (the 4 mg $149 promo ended Aug 31, 2026); $299 for 9 mg and 25 mg. 30-day supply Published maintenance dose $299/mo 30-day supply $299 per 30 days at this quoted rate Checked Sep 30, 2026 At 25 mg Wegovy pill (oral semaglutide) NovoCare (Novo Nordisk) · Manufacturer direct Published price at 25 mg Price conditions Published price at 25 mg $149/mo for 1.5 mg; $199 for 4 mg (the 4 mg $149 promo ended Aug 31, 2026); $299 for 9 mg and 25 mg. $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg). 30-day supply	No reviewed tablet formulation in this brand record.

All Wegovy offers All Wegovy HD offers

How these quotes are selected

For each price basis, we prefer a recently checked manufacturer-direct quote, then a recently checked provider quote for that brand and formulation. Within each group, documented 30-day costs come first, lowest to highest. Quotes without a documented supply period have no cost rank. Older quotes appear as dated references only when no current quote is tracked. Providers may differ between entry and maintenance prices. Missing maintenance prices are never replaced with entry prices. Compounded products, combined brand quotes, and membership-only fees are excluded. Prices at different doses are not equivalent treatment costs; confirm supply length, eligibility, and added fees.

Every cash quote was checked on or after Sep 26, 2026. Each quote shows its own check date. A quoted maintenance dose is not a dosing recommendation. Our methodology

US prescribing information

Approved uses by formulation

Eligibility, contraindications, and warnings are in each product's full prescribing information.

Wegovy vs Wegovy HD: reviewed approved uses by formulation
Compare	Wegovy	Wegovy HD
Injection	Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular risk reduction in eligible adults; noncirrhotic MASH with moderate to advanced liver fibrosis in adults (accelerated approval). US prescribing information (Wegovy Injection prescribing information) Reviewed Sep 6, 2026	Weight management in adults with obesity, or overweight with a weight-related condition. The 7.2 mg dose is for adults who tolerate 2.4 mg and need additional weight reduction. US prescribing information (Wegovy HD 7.2 mg injection prescribing information) Reviewed Sep 22, 2026
Tablet	Weight management and cardiovascular risk reduction in eligible adults. The tablet is not labeled for MASH or pediatric use. US prescribing information (Wegovy Tablet prescribing information) Reviewed Sep 6, 2026	No reviewed tablet label in this brand record. Ingredient record

Full evidence and safety information

Semaglutide: evidence & safety

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.

Active ingredient

SemaglutideGLP-1

How it is taken

Injection

Once weekly

Tablet

Once daily, on an empty stomach

7.2 mg injection

Once weekly

Manufacturer

Novo Nordisk

Treatment & dose

Change

Semaglutide (Wegovy)2.4 mg weekly injection

−15.6%

Semaglutide (Wegovy HD)7.2 mg weekly injection

−18.7%

PlaceboWeekly injection

−3.9%

Injection evidence

−14.9%

STEP 1 · -14.9% at 68 wks

2.4 mg weekly (Wegovy)

Accounts for treatment discontinuation

−18.7%

STEP UP · -18.7% at 72 wks

7.2 mg weekly (Wegovy HD)

Accounts for treatment discontinuation

Tablet evidence

−13.6%

OASIS 4 · -13.6% at 64 wks

25 mg daily (Wegovy tablet)

Accounts for treatment discontinuation

No reviewed weight-loss result for this brand and formulation.

Injection prices

Advertised entry price

$199/fill initially

28-day supply

≈ $213.21 per 30 days at this quoted rate

Offer through Dec 31, 2026

Checked Sep 30, 2026

Wegovy pen (standard doses 0.25-2.4 mg)

NovoCare (Novo Nordisk) · Manufacturer direct

first two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026

Price conditions

first two monthly fills at 0.25 or 0.5 mg for new patients, prescribed by Dec 31, 2026

After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply.

28-day supply

Published maintenance dose

$349/28 days

28-day supply

≈ $373.93 per 30 days at this quoted rate

Checked Sep 30, 2026

At 2.4 mg

Wegovy pen (standard doses 0.25-2.4 mg)

NovoCare (Novo Nordisk) · Manufacturer direct

Published price at 2.4 mg

Price conditions

Published price at 2.4 mg

After the introductory offer, standard doses cost $349 per box of four weekly pens. Wegovy HD (7.2 mg) is $399. Eligibility and restrictions apply.

One price for every standard dose (0.25-2.4 mg).

28-day supply

Advertised entry price

$399/28 days

28-day supply

≈ $427.50 per 30 days at this quoted rate

Checked Sep 30, 2026

Wegovy HD pen (7.2 mg)

NovoCare (Novo Nordisk) · Manufacturer direct

self-pay cash, 7.2 mg dose

Price conditions

self-pay cash, 7.2 mg dose

One box contains four weekly pens. This is the HD maintenance dose, not a treatment starting dose. The $199 introduction applies only to 0.25 and 0.5 mg standard Wegovy. Prescription, eligibility and restrictions apply.

28-day supply

Published maintenance dose

$399/28 days

28-day supply

≈ $427.50 per 30 days at this quoted rate

Checked Sep 30, 2026

At 7.2 mg

Wegovy HD pen (7.2 mg)

NovoCare (Novo Nordisk) · Manufacturer direct

Published price at 7.2 mg

Price conditions

Published price at 7.2 mg

28-day supply

Tablet prices

Advertised entry price

from $149/mo

30-day supply

$149 per 30 days at this quoted rate

Checked Sep 30, 2026

Wegovy pill (oral semaglutide)

NovoCare (Novo Nordisk) · Manufacturer direct

self-pay cash, lowest dose (1.5 mg)

Price conditions

self-pay cash, lowest dose (1.5 mg)

$149/mo for 1.5 mg; $199 for 4 mg (the 4 mg $149 promo ended Aug 31, 2026); $299 for 9 mg and 25 mg.

30-day supply

Published maintenance dose

$299/mo

30-day supply

$299 per 30 days at this quoted rate

Checked Sep 30, 2026

At 25 mg

Wegovy pill (oral semaglutide)

NovoCare (Novo Nordisk) · Manufacturer direct

Published price at 25 mg

Price conditions

Published price at 25 mg

$149/mo for 1.5 mg; $199 for 4 mg (the 4 mg $149 promo ended Aug 31, 2026); $299 for 9 mg and 25 mg.

$149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg).

30-day supply

No reviewed tablet formulation in this brand record.

Injection

Weight management in eligible adults and adolescents 12+ with obesity; cardiovascular risk reduction in eligible adults; noncirrhotic MASH with moderate to advanced liver fibrosis in adults (accelerated approval).

US prescribing information

Reviewed Sep 6, 2026

Weight management in adults with obesity, or overweight with a weight-related condition. The 7.2 mg dose is for adults who tolerate 2.4 mg and need additional weight reduction.

US prescribing information

Reviewed Sep 22, 2026

Tablet

Weight management and cardiovascular risk reduction in eligible adults. The tablet is not labeled for MASH or pediatric use.

US prescribing information

Reviewed Sep 6, 2026

No reviewed tablet label in this brand record. Ingredient record